Johnson & Johnson (JNJ) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - General

24/25

Growth 5 Margin 5 Expansion 5 Platform 4 Financial 5

latest quarter score

Earnings Reports

24
Johnson & Johnson (JNJ) Q2 2026: Innovative Medicine Drives $400M Guidance Raise, MedTech Faces Cardiovascular Drag
July 15, 2026
22
Johnson & Johnson (JNJ) Q1 2026: Icotide Launch Drives 7.4% Innovative Medicine Growth, Raising Full-Year Outlook
April 14, 2026
24
Johnson & Johnson (JNJ) Q4 2025: Oncology Surges 21% as Portfolio Shift Targets Double-Digit Growth
January 21, 2026
24
Johnson & Johnson (JNJ) Q3 2025: Orthopedics Separation Targets 75bps Margin Lift, Accelerating MedTech Focus
October 14, 2025
20
Johnson & Johnson (JNJ) Q2 2025: Oncology Jumps 22% as Portfolio Depth Offsets Stellara LOE
July 17, 2025
21
Johnson & Johnson (JNJ) Q1 2025: Diversified Model Delivers Growth Despite Stellara Erosion and Margin Headwinds
June 10, 2025

Browse all companies